Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Collier

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.
European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 14, 2017
Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional RestorationD Luke Fischer, Christopher J Kemp, Allyson Cole-Strauss, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 29, 2025
Disease-modifying, multidimensional efficacy of putaminal Ca<sub>V</sub>1.3-shRNA gene therapy in aged parkinsonism male and female macaquesKathy Steece-Collier, Margaret E Caulfield, Molly J Vander Werp, et al.
Rejuvenation Research|April 8, 2010
Cellular repair in the parkinsonian nonhuman primate brainDonald Eugene Redmond, Stephanie Weiss, John D Elsworth, et al.
The American Journal of Cardiology|January 12, 2023
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)João Pedro Ferreira, John G F Cleland, Nicolas Girerd, et al.
European Journal of Heart Failure|March 18, 2017
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trialArnaud Olivier, Bertram Pitt, Nicolas Girerd, et al.
Neurobiology of Disease|November 14, 2020
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in ratsNatosha M Mercado, Jennifer A Stancati, Caryl E Sortwell, et al.
Translational Psychiatry|March 8, 2022
Behavioral phenotyping of a rat model of the BDNF Val66Met polymorphism reveals selective impairment of fear memoryEmily J Jaehne, Jessica N Kent, Emily J Antolasic, et al.
Scientific Reports|November 29, 2017
Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein OverexpressionD Luke Fischer, Fredric P Manfredsson, Christopher J Kemp, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.
European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 14, 2017
Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional RestorationD Luke Fischer, Christopher J Kemp, Allyson Cole-Strauss, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 29, 2025
Disease-modifying, multidimensional efficacy of putaminal Ca<sub>V</sub>1.3-shRNA gene therapy in aged parkinsonism male and female macaquesKathy Steece-Collier, Margaret E Caulfield, Molly J Vander Werp, et al.
Rejuvenation Research|April 8, 2010
Cellular repair in the parkinsonian nonhuman primate brainDonald Eugene Redmond, Stephanie Weiss, John D Elsworth, et al.
The American Journal of Cardiology|January 12, 2023
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)João Pedro Ferreira, John G F Cleland, Nicolas Girerd, et al.
European Journal of Heart Failure|March 18, 2017
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trialArnaud Olivier, Bertram Pitt, Nicolas Girerd, et al.
Neurobiology of Disease|November 14, 2020
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in ratsNatosha M Mercado, Jennifer A Stancati, Caryl E Sortwell, et al.
Translational Psychiatry|March 8, 2022
Behavioral phenotyping of a rat model of the BDNF Val66Met polymorphism reveals selective impairment of fear memoryEmily J Jaehne, Jessica N Kent, Emily J Antolasic, et al.
Scientific Reports|November 29, 2017
Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein OverexpressionD Luke Fischer, Fredric P Manfredsson, Christopher J Kemp, et al.
Pageof 9